Patents Assigned to Neemo Inc
  • Publication number: 20190144846
    Abstract: By this invention, for the first time, a method for high-efficiency site-specific genetic engineering, utilizing either native or heterologous CRISPR-Cas9 systems, in the anaerobic bacterium Clostridium pasteurianum, is provided. Application of CRISPR-Cas9 systems has revolutionized genome editing across all domains of life. Here we report implementation of the heterologous Type CRISPR-Cas9 system in Clostridium pasteurianum for markerless genome editing. Since 74% of species harbor CRISPR-Cas loci in Clostridium, we also explored the prospect of co-opting host-encoded CRISPR-Cas machinery for genome editing. Motivation for this work was bolstered from the observation that plasmids expressing heterologous cas9 result in poor transformation of Clostridium. To address this barrier and establish proof-of-concept, we focus on characterization and exploitation of the C. pasteurianum Type CRISPR-Cas system.
    Type: Application
    Filed: July 4, 2017
    Publication date: May 16, 2019
    Applicant: Neemo Inc
    Inventors: Michael E. Pyne, Mark Bruder, Murray Moo-Young, Duane Chung, C. Perry Chou